These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12680233)

  • 1. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma.
    Visca P; Sebastiani V; Pizer ES; Botti C; De Carli P; Filippi S; Monaco S; Alo PL
    Anticancer Res; 2003; 23(1A):335-9. PubMed ID: 12680233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue.
    Alò PL; Visca P; Botti C; Galati GM; Sebastiani V; Andreano T; Di Tondo U; Pizer ES
    Am J Clin Pathol; 2001 Jul; 116(1):129-34. PubMed ID: 11447743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival.
    Younes M; Juarez D; Lechago LV; Lerner SP
    Anticancer Res; 2001; 21(1B):575-8. PubMed ID: 11299807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma.
    Visca P; Sebastiani V; Botti C; Diodoro MG; Lasagni RP; Romagnoli F; Brenna A; De Joannon BC; Donnorso RP; Lombardi G; Alo PL
    Anticancer Res; 2004; 24(6):4169-73. PubMed ID: 15736468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
    Suzuki K; Morita T; Tokue A
    Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
    Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma.
    Mineta H; Miura K; Takebayashi S; Misawa K; Araki K; Misawa Y; Ueda Y
    Anticancer Res; 2002; 22(6B):3489-94. PubMed ID: 12552944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
    Zhou JT; Cai ZM; Li NC; Na YQ
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
    Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
    J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
    Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
    Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
    Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
    Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
    BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.